Objective: This retrospective service evaluation investigated the impact of engagement with an app-based digital weight loss program on weight loss outcomes among individuals using GLP-1 receptor ...
Off-label use of medications like Ozempic, Wegovy, Mounjaro, and Zepbound is becoming increasingly common to address weight management, insulin resistance, and diabetes related complications in type 1 ...
Ships sit under construction at a HD Hyundai Mipo Dockyard Co. shipyard in Ulsan, South Korea, on Sunday, March 30, 2025. The White House is considering whether to purchase foreign-made ships for the ...
We are building oncology’s first non-pharma treatment layer, helping patients live longer and better, from diagnosis through survivorship. Clinically validated and delivered daily, Complement 1 ...
WEST LAFAYETTE − Purdue women's basketball added the size it needed to complement returning center Avery Gordon. Six-foot-5 center Anjela Minja announced on social media she's committed to the ...
LAS VEGAS — Off-label use of GLP-1 drugs by people with type 1 diabetes (T1D) did not lead to diabetic ketoacidosis (DKA) or pancreatitis in a large 1-year single-center study. Moreover, GLP-1 agonist ...
It may sound hard to believe, but the almost trillion-dollar U.S. military is struggling to fight cheap drones in its war with Iran. Iran has also hit U.S. military bases with these drones, including ...
Not too long ago I would have said I was one of the least likely people to be tempted by GLP-1s like Wegovy or Zepbound. My weight has always been average. I have no medical conditions, and more than ...
Add Yahoo as a preferred source to see more of our stories on Google. Donald Trump is known for his hasty (and frequent) posts on social media. But in recent months, select posts have concluded with ...
What began as an unexpected observation and “side effect” of some medications converged with decades of addiction neuroscience: GLP-1 receptor agonist medications like Ozempic apparently reduce ...
GLP‑1 drugs may fight addiction across every major substance, according to a study of 600,000 people
A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes. He didn’t use a patch. He ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results